PL377995A1 - Zmniejszona dawka tolterodyny i innych środków przeciwmuskarynowych do leczenia zaburzeń układu moczowego - Google Patents

Zmniejszona dawka tolterodyny i innych środków przeciwmuskarynowych do leczenia zaburzeń układu moczowego

Info

Publication number
PL377995A1
PL377995A1 PL377995A PL37799504A PL377995A1 PL 377995 A1 PL377995 A1 PL 377995A1 PL 377995 A PL377995 A PL 377995A PL 37799504 A PL37799504 A PL 37799504A PL 377995 A1 PL377995 A1 PL 377995A1
Authority
PL
Poland
Prior art keywords
tolterodine
treating urinary
urinary disorders
reduced dose
antimuscarinic agents
Prior art date
Application number
PL377995A
Other languages
English (en)
Polish (pl)
Inventor
Barbara H. Korberly
Susan M. Danehower
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32771960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL377995(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Publication of PL377995A1 publication Critical patent/PL377995A1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL377995A 2003-01-22 2004-01-14 Zmniejszona dawka tolterodyny i innych środków przeciwmuskarynowych do leczenia zaburzeń układu moczowego PL377995A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44169003P 2003-01-22 2003-01-22

Publications (1)

Publication Number Publication Date
PL377995A1 true PL377995A1 (pl) 2006-02-20

Family

ID=32771960

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377995A PL377995A1 (pl) 2003-01-22 2004-01-14 Zmniejszona dawka tolterodyny i innych środków przeciwmuskarynowych do leczenia zaburzeń układu moczowego

Country Status (17)

Country Link
US (2) US20060047007A1 (https=)
EP (1) EP1589958B2 (https=)
JP (1) JP2006515607A (https=)
KR (1) KR20050096147A (https=)
CN (1) CN1741796A (https=)
AT (1) ATE432070T1 (https=)
AU (1) AU2004206110A1 (https=)
BR (1) BRPI0406861A (https=)
CA (1) CA2514022C (https=)
DE (1) DE602004021233D1 (https=)
ES (1) ES2324712T5 (https=)
IL (1) IL169362A0 (https=)
MX (1) MXPA05007767A (https=)
PL (1) PL377995A1 (https=)
TW (1) TW200418447A (https=)
WO (1) WO2004064821A1 (https=)
ZA (1) ZA200505026B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
DK2210605T3 (en) * 2003-11-04 2017-05-22 Tcd Royalty Sub Llc Daily single dose doses of trospium.
ES2322148T3 (es) * 2004-08-11 2009-06-17 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias.
PT1986642E (pt) * 2006-02-13 2014-01-30 Orient Pharma Samoa Co Ltd Combinação de agonista do receptor alfa-2 (clonidina) e um agente antimuscarínico (oxibutinina) para o tratamento de sialorreia
WO2009019599A2 (en) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
WO2011109403A1 (en) * 2010-03-01 2011-09-09 Xenoport, Inc. Use of (3r)-4-{[(1s)-2-methyl-1- (2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
JP2000515525A (ja) 1996-07-19 2000-11-21 アベーグ,グンナー 尿と胃腸の疾患の治療におけるs(―)―トルテロジン
SK287111B6 (sk) * 1998-08-27 2009-12-07 Pharmacia & Upjohn Ab Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
NZ518309A (en) * 1999-11-11 2003-05-30 Pharmacia Ab Controlled release tolterodine formulation that releases not less than 80% of the active compound in under 18 hours

Also Published As

Publication number Publication date
ES2324712T5 (es) 2012-06-08
TW200418447A (en) 2004-10-01
BRPI0406861A (pt) 2006-01-03
DE602004021233D1 (de) 2009-07-09
ES2324712T3 (es) 2009-08-13
JP2006515607A (ja) 2006-06-01
CN1741796A (zh) 2006-03-01
KR20050096147A (ko) 2005-10-05
EP1589958B1 (en) 2009-05-27
WO2004064821A1 (en) 2004-08-05
ZA200505026B (en) 2006-07-26
CA2514022C (en) 2010-07-13
ATE432070T1 (de) 2009-06-15
CA2514022A1 (en) 2004-08-05
US20060047007A1 (en) 2006-03-02
US20070155838A1 (en) 2007-07-05
MXPA05007767A (es) 2006-01-31
AU2004206110A1 (en) 2004-08-05
EP1589958A1 (en) 2005-11-02
EP1589958B2 (en) 2012-04-11
IL169362A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
MXPA04003866A (es) Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva.
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
EP1600167A3 (en) A pyrrolidineacetamide derivative alone in combination for treatment of CNS disorders
WO2002038142A3 (en) Serotonergic compositions and methods for treatment of mild cognitive impairment
PY0108909A (es) Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero
PL366430A1 (en) Sustained release formulations of oxymorphone
AU3846901A (en) Oral, nasal and pulmonary dosage formualtions of copolymer 1
WO2002066427A3 (en) (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof
GB0406384D0 (en) Composition for reducing appetite in mammals comprising proxyanidin
ZA200505026B (en) Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
UA42719C2 (uk) Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб
WO2003049667A3 (en) The method of treating cancer
WO2003015690A3 (en) Method for treating primary insomnia
CA2432177A1 (en) Drug for prevention and/or therapy of endometriosis
JPS56142213A (en) Pharmacuetical blend for treating parkinsonism syndrome
MXPA04001805A (es) Nueva forma de dosificacion oral de liberacion prolongada.
WO2002091990A3 (en) Prevention of addiction in pain management
IL162391A0 (en) Method of treatment
EP1260221A3 (en) Combination treatment for depression and anxiety
WO2001028541A3 (en) Composition comprising sildenafil and l-arginine
WO2001039760A3 (en) Method of treating batten disease
EP1584333A3 (en) Use of acetylcoenzime A inhibitors for treating Alzheimer's disease
MXPA02007454A (es) Compuestos utiles para tratamiento o prevencion de una enfermedad mediada por el alfa-2b-adrenoceptor.
RU2006146071A (ru) Средство для устранения фактора циркуляторной дисфункции

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)